Delivery Order SPE2DB20D2104-SPE2DB25FMYGL
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) valued at $10,304.26. This is a firm fixed-price delivery order with no set-aside designation, reflecting competitive procurement practices. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Gemtesa 75 mg tablets (90-unit quantity) with a ceiling value of $8,291.23. This firm fixed-price delivery order, with an ultimate completion date of August 4, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award was made through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) under a firm fixed-price contract valued at $42,751.81. This non-set-aside delivery order is expected to be completed by August 1, 2025, with performance occurring at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract represents a child award under the company's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count) on August 8, 2025, with a ceiling value of $3,831.81 and an ultimate completion date of August 11, 2025. This non-set-aside, competitively awarded delivery order utilizes firm fixed pricing and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $3,869.18 to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (30-count supply) on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price, competitively awarded contract involves no set-aside designation and specifies Conshohocken, Pennsylvania as the place of performance. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) valued at $19,403.29. This firm fixed-price delivery order, with an ultimate completion date of August 15, 2025, represents a non-competitive set-aside award and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $4,983.09 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Gemtesa 75 mg tablets (90-count units), with completion scheduled for July 29, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 global pharmaceutical support vehicle running through December 2026. The...
- The Defense Logistics Agency awarded a delivery order valued at $7,747.10 to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90 count) on August 12, 2025, with completion scheduled for August 13, 2025. This competitively awarded, firm fixed price contract represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December...
- The Defense Logistics Agency awarded a $19.2K delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Gemtesa 75 mg tablets (90-unit quantity), with completion scheduled for July 30, 2025. This is a firm fixed price, non-set-aside contract performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a discrete purchase under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order valued at $4,232.99 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (30-count) on July 29, 2025, with an ultimate completion date of July 30, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award to the pharmaceutical distributor's Corporate Office located in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMYGLDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Gemtesa 75 mg tablets (90-count packaging) with a ceiling value of $3,197.73. This firm fixed-price delivery order, which is expected to be completed by August 20, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (valued at $999,999,999.00 through December 2026). The award was made through competitive procurement with no set-aside designation, and performance will be executed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, continues to serve as a critical vendor for federal medical procurement needs through the DLA Medical Supply Chain. This delivery order for Gemtesa, a prescription urological medication, exemplifies the company's role in supplying a comprehensive range of pharmaceutical products to support military and veteran healthcare systems. The competitively awarded transaction demonstrates AmerisourceBergen's capability to fulfill federal medical supply requirements across multiple therapeutic domains and reinforces its position as a primary pharmaceutical vendor for defense healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.2k | 8/19/25 |